Cargando…

New potential targeted strategies in small cell lung cancer

Detalles Bibliográficos
Autores principales:	de Toro, María, Pangua, Cristina, Serrano-Montero, Gloria, Lara, Miguel Ángel, Rogado, Jacobo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183393/ https://www.ncbi.nlm.nih.gov/pubmed/37197617 http://dx.doi.org/10.21037/tlcr-23-64

Ejemplares similares

Characteristics and outcome of lung cancer patients and Covid-19 infection in a second-level hospital during the first 3 months of the pandemic()
por: Rogado, Jacobo, et al.
Publicado: (2020)

Características y evolución de los pacientes con cáncer de pulmón e infección Covid-19 en un hospital de segundo nivel durante los 3 primeros meses de pandemia
por: Rogado, Jacobo, et al.
Publicado: (2020)

Prevalence of thrombosis in patients with cancer and SARS-CoV-2 infection
por: Obispo, Berta, et al.
Publicado: (2022)

Prevalence of thrombosis in patients with cancer and SARS-CoV-2 infection
por: Obispo, Berta, et al.
Publicado: (2022)

Covid-19 and lung cancer: A greater fatality rate?
por: Rogado, Jacobo, et al.
Publicado: (2020)

New perspectives in the management of small cell lung cancer
por: Pangua, Cristina, et al.
Publicado: (2022)

COVID-19 mortality in cancer patients in a Madrid hospital during the first 3 weeks of the epidemic()
por: Lara Álvarez, Miguel Ángel, et al.
Publicado: (2020)

Mortalidad por COVID-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemia
por: Lara Álvarez, Miguel Ángel, et al.
Publicado: (2020)

Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors
por: Rogado, Jacobo, et al.
Publicado: (2021)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

1766P COVID-19 and lung cancer: What do we know?
por: Serrano, G., et al.
Publicado: (2020)

1771P Do breast cancer patients with COVID-19 have a poor prognosis? Experience in a hospital in Madrid
por: Obispo, B., et al.
Publicado: (2020)

The Other Cost of the Pandemic
por: Obispo, Berta, et al.
Publicado: (2022)

Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid
por: Rogado, J., et al.
Publicado: (2020)

Notching up a new therapeutic strategy for Non-Small Cell Lung Carcinoma (NSCLC)
por: Maraver, Antonio, et al.
Publicado: (2012)

1685P Is cancer what determines COVID-19 oncological patient’s outcome or are other external factors involved? Experience in a hospital in Madrid, Spain
por: Rogado, J., et al.
Publicado: (2020)

1573P First wave mortality data versus full pandemic period from the COVID-CANCER HUIL study
por: Serrano-Montero, G., et al.
Publicado: (2021)

1576P COVID-CANCER HUIL - Registry of oncological patients with diagnosis of COVID-19 at Hospital Universitario Infanta Leonor in Madrid (Spain): One year of pandemic
por: Rogado, J., et al.
Publicado: (2021)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
por: Kujtan, Lara, et al.
Publicado: (2023)

Incidence of Thromboembolic Events in Cancer Hospitalized Patients With COVID-19
por: Rogado, Jacobo, et al.
Publicado: (2021)

In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer
por: Bindal, Poorva, et al.
Publicado: (2020)

Targeting the adenosine 2A receptor in non-small cell lung cancer: shooting with blank bullets?
por: Garcia-Lorenzo, Esther, et al.
Publicado: (2023)

Defining the Optimal Management Strategy for Small Renal Masses
por: Dall’Era, Marc, et al.
Publicado: (2021)

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer
por: Sattler, Martin, et al.
Publicado: (2023)

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Implications of the success of EGFR-targeted therapy in advanced non–small cell lung cancer for its application to the adjuvant setting
por: Takeda, Masayuki
Publicado: (2020)

Radical segmentectomy as a potential alternative surgical treatment with curative intent in early-stage non-small cell lung cancer
por: Koike, Terumoto, et al.
Publicado: (2020)

Lung cancer in India: Current status and promising strategies
por: Parikh, P. M., et al.
Publicado: (2016)

Surgical treatment of small-sized non-small cell lung cancer—a dilemma for surgeons
por: Kodama, Ken, et al.
Publicado: (2020)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Surgery for early-stage small cell lung cancer: is it worth it?
por: Vyfhuis, Melissa A. L., et al.
Publicado: (2019)

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
por: Wang, Yanye, et al.
Publicado: (2020)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Targeting hypoxia in tumor: a new promising therapeutic strategy
por: Bosco, Maria Carla, et al.
Publicado: (2020)

Proton stereotactic body radiation therapy for non-small cell lung cancer
por: Diwanji, Tejan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0h9lno4lft6v4tr5sqk81t0pb